Caricamento...
Radiopharmaceutical Formulation and Preclinical Testing of (68)Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial
The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using (68)Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply with the reg...
Salvato in:
| Pubblicato in: | Pharmaceuticals (Basel) |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
MDPI
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8235783/ https://ncbi.nlm.nih.gov/pubmed/34208516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph14060575 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|